256 related articles for article (PubMed ID: 16491483)
1. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
Hao XK; Liu JY; Yue QH; Wu GJ; Bai YJ; Yin Y
Prostate; 2006 Jun; 66(8):858-66. PubMed ID: 16491483
[TBL] [Abstract][Full Text] [Related]
2. Specific tumour localisation of a huA33 antibody--carboxypeptidase A conjugate and activation of methotrexate-phenylalanine.
Deckert PM; Bornmann WG; Ritter G; Williams C; Franke J; Keilholz U; Thiel E; Old LJ; Bertino JR; Welt S
Int J Oncol; 2004 May; 24(5):1289-95. PubMed ID: 15067353
[TBL] [Abstract][Full Text] [Related]
3. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
4. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate-alpha-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate.
Vitols KS; Haag-Zeino B; Baer T; Montejano YD; Huennekens FM
Cancer Res; 1995 Feb; 55(3):478-81. PubMed ID: 7834611
[TBL] [Abstract][Full Text] [Related]
6. [The solid-phase synthesis of methotrexate-alpha-peptides].
Shi PT; Hao XK; Chen Y; Zhang YH; Tao QY
Yao Xue Xue Bao; 1997; 32(2):106-9. PubMed ID: 11243192
[TBL] [Abstract][Full Text] [Related]
7. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
8. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
9. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
Biela BH; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
[TBL] [Abstract][Full Text] [Related]
11. Expression and characterization of human pancreatic preprocarboxypeptidase A1 and preprocarboxypeptidase A2.
Laethem RM; Blumenkopf TA; Cory M; Elwell L; Moxham CP; Ray PH; Walton LM; Smith GK
Arch Biochem Biophys; 1996 Aug; 332(1):8-18. PubMed ID: 8806703
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
13. Tumor-selective prodrug activation by fusion protein-mediated catalysis.
Bosslet K; Czech J; Hoffmann D
Cancer Res; 1994 Apr; 54(8):2151-9. PubMed ID: 8174122
[TBL] [Abstract][Full Text] [Related]
14. Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy.
Li B; Zhang LJ; Zhang ZL; Long M; Ren JH; Lin F; Wang X; Wei JX; Dong K; Zhang HZ
Anticancer Drugs; 2011 Mar; 22(3):213-22. PubMed ID: 21150773
[TBL] [Abstract][Full Text] [Related]
15. Design, construction, and in vitro analysis of A33scFv::CDy, a recombinant fusion protein for antibody-directed enzyme prodrug therapy in colon cancer.
Coelho V; Dernedde J; Petrausch U; Panjideh H; Fuchs H; Menzel C; Dübel S; Keilholz U; Thiel E; Deckert PM
Int J Oncol; 2007 Oct; 31(4):951-7. PubMed ID: 17786329
[TBL] [Abstract][Full Text] [Related]
16. Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.
Perron MJ; Page M
Br J Cancer; 1996 Feb; 73(3):281-7. PubMed ID: 8562331
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
[TBL] [Abstract][Full Text] [Related]
18. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
Asai T; Trinh R; Ng PP; Penichet ML; Wims LA; Morrison SL
Biomol Eng; 2005 Feb; 21(6):145-55. PubMed ID: 15748688
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
20. Expression of single-chain Fv gene specific for gamma-seminoprotein by RTS and its biological activity identification.
Han Y; Haun Y; Deng J; Gao F; Pan B; Cui D
Biotechnol Prog; 2006; 22(4):1084-9. PubMed ID: 16889383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]